CRISPR Partners with Capsida to Develop Gene-editing Therapies

CRISPR Partners with Capsida to Develop Gene-editing Therapies

297703

CRISPR Partners with Capsida to Develop Gene-editing Therapies

CRISPR Therapeutics has joined forces with Capsida Biotherapeutics to discover and develop new gene-editing therapies for Friedreich’s ataxia (FA) and familial amyotrophic lateral sclerosis (ALS). The partnership seeks to combine CRISPR Therapeutics’ gene-editing expertise using its proprietary CRISPR/Cas9 platform with Capsida’s tissue-targeted, adeno-associated virus (AAV)-based gene therapies. “The combination of Capsida’s AAV engineering platform and CRISPR Therapeutics’ gene-editing platform has the potential to enable transformative gene-edited therapies for patients with neurological diseases,” Samarth Kulkarni, PhD, CRISPR…

You must be logged in to read/download the full post.